Biosynth Unveils Safer Diagnostic Materials to Stabilize Medical Supply Chains

Biosynth Unveils Safer Diagnostic Materials to Stabilize Medical Supply Chains

2026-11-16 companies

Staad, Monday, 16 November 2026.
Marking its 60th anniversary, Biosynth introduced non-infectious, animal-free diagnostic reagents at MEDICA 2026, eliminating critical biological handling hazards while strengthening vulnerable healthcare supply chains worldwide.

A Legacy of Innovation at 60

Biosynth, the Swiss-headquartered life sciences company, marked its 60th anniversary at MEDICA 2026 by unveiling a significant expansion of its in vitro diagnostics (IVD) portfolio [1]. The company, founded in 1966 with headquarters in Staad, St. Gallen, Switzerland [3], has evolved from a reagent supplier into a global partner for pharmaceutical, biotechnology, diagnostic, and research organizations [3]. At the heart of this expansion is the introduction of recombinant materials, tunable enzyme substrates, and animal-free reagent alternatives, designed to address both technical and supply chain challenges in diagnostic development [1].

New Materials Address Critical Supply Chain Vulnerabilities

The expanded portfolio includes monoclonal antibodies, recombinant horseradish peroxidase, recombinant rheumatoid factor IgM, and autoimmune antigens, alongside hepatitis A virus (HAV) IgM monoclonal antibodies developed as non-infectious alternatives to native HAV materials [1]. These innovations are particularly timely, as the healthcare and biotechnology sectors continue to grapple with supply chain disruptions that threaten the reliability of critical diagnostic components [alert! ‘specific reason’: While supply chain vulnerabilities are well-documented in the industry, no specific recent disruption data is cited in the provided sources]. Philip Noone, CEO of Biosynth’s Biologics Division, emphasized the need for consistent materials and reliable access to critical components as programs advance toward commercialization [1].

Technical Breakthroughs in Diagnostic Development

Biosynth’s new offerings span immunoassay raw materials, antigens, plasma, and specialty solutions tailored for every stage of the IVD workflow—from assay design and optimization to scale-up and commercialization [2]. The company’s expertise in biologics and specialty chemicals enables it to provide complementary scientific disciplines that help customers solve complex material challenges [1]. Holger Olbrück, Vice President of Strategic Accounts, noted that understanding the specific requirements of an assay allows developers to identify materials and solutions suited to their needs, manufactured reliably in volumes demanded by the market [1].

Global Reach and Industry Impact

With a global footprint spanning Switzerland, the UK, Slovakia, China, the Netherlands, the US, Austria, Germany, and Ireland [3], Biosynth operates as a critical link in the life sciences supply chain [3]. The company’s operational portfolio includes carbohydrates, nucleosides, enzyme substrates, natural products, building blocks, biochemicals, custom synthesis, GMP manufacturing, and CDMO services [3]. This comprehensive infrastructure positions Biosynth to support diagnostic developers in reducing complexity, maintaining momentum, and accelerating progress from research to commercial supply [2].

A Showcase at MEDICA 2026

Biosynth’s expanded IVD portfolio and capabilities are being showcased at MEDICA 2026, the world’s largest medical trade fair, held in Staad, St. Gallen, Switzerland, from November 16–19, 2026 [1]. The event coincides with the company’s 60th anniversary and provides a platform for Biosynth to engage with diagnostic developers, researchers, and industry stakeholders [1][3]. Attendees can explore how Biosynth’s reagents, expertise, and manufacturing capabilities can support their next project [2].

Sources


biotechnology diagnostics